Pancreatic Cancer Practice Guidelines 2022

DOI Web Site 40 References
  • OZAKA Masato
    Department of Hepato-Biliary-Pancreatic Medicine, Gastroenterology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • UEMURA Keiichi
    Department of Psychiatry, Tonan Hospital
  • TAGAMI Keita
    Department of Palliative Medicine, Tohoku University School of Medicine
  • TSUJI Tetsuya
    Department of Rehabilitation Medicine, Keio University School of Medicine
  • MORI Masanori
    Palliative Care Team, Seirei Mikatahara General Hospital
  • YOKOKAWA Takashi
    Department of Pharmacy, Cancer Institute Hospital of Japanese Foundation for Cancer Research
  • OYAKAWA Takuya
    Division of Cardiology, Shizuoka Cancer Center
  • MITSUNAGA Shuichi
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • FUJIMORI Maiko
    Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center
  • SAKAMOTO Hatoe
    Supportive Care Center, National Cancer Center Hospital East
  • SHIMIZU Yoichi
    Department of Nursing, National Cancer Center Hospital

Bibliographic Information

Other Title
  • 支持緩和療法
  • -supportive and palliative therapy-

Abstract

<p>Since many patients with pancreatic cancer are diagnosed at a time when the lesion is unresectable and present with a variety of symptoms at diagnosis, it is necessary to initiate interventions aimed at palliation of symptoms and improvement of quality of life in the early stages of the disease. In the Pancreatic Cancer Treatment Guideline 2022, clinical questions (CQs) were defined for approaches required for early palliative treatment in the treatment of patients with pancreatic cancer (mental and psychological care and advance care planning for patients with pancreatic cancer and their families, and the utility of communication skills training) and for symptom palliation (pain management, peripheral nerve damage control, cachexia, thrombosis and ascites management) in the treatment of patients with pancreatic cancer, respectively. Although there is insufficient evidence for any of the CQs, they are considered important in the management of patients with pancreatic cancer, and a systematic review resulted in recommendations.</p>

Journal

  • Suizo

    Suizo 38 (2), 138-146, 2023-04-28

    Japan Pancreas Society

References(40)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top